NCT06132776UnknownNot Applicable
High Tone Therapy for Chemotherapy-induced Neuropathy in Breast Cancer Patients
Vienna Hospital Association1 site in 1 country160 target enrollmentStarted: November 3, 2023Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 160
- Locations
- 1
- Primary Endpoint
- Alleviation of paresthesias (VAS)
Study Overview
Brief Summary
The HiToP ® 191 PNP an certified device licensed for the treatment of neuropathia.
The home-based treatment is to be performed only in accordance with the approved Investigational Plan (CIP) on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
The study is multicenter, randomized, double-blind, and placebo-controlled.
Primary Objective: Comparison of the change of paresthesias from baseline until end of therapy between the two patient groups, assessed by questionnaires
Secondary Objectives: Further symptoms of neuropathy as well as on health-related quality of life.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •- Patients with histologically verified breast cancer and neoadjuvant or adjuvant treatment with a taxane derivate (e.g., Paclitaxel, Docetaxel): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,
- •Cumulative dose of at least 3 cycles
- •Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects
- •Life expectancy of at least 3 months
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying)
- •Ability to walk (with or without aids)
- •European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2
- •Intensity of paresthesias of > 3/10 on the Visual Analog Scale (VAS)
Exclusion Criteria
- •- Prevalent neuropathy of different etiology
- •Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators
- •Minors or persons unable to give informed consent
- •Current neurotoxic medication
- •Implanted pacemakers or defibrillators
- •Pregnancy
- •Wounds in the area to be treated, acute local or systemic infection
- •Peripheral arterial occlusive disease > grade 2
Arms & Interventions
Verum group
Experimental
Intervention: HiToP 191 PNP (Device)
Placebo group
Placebo Comparator
Intervention: Placebo device (Device)
Outcomes
Primary Outcomes
Alleviation of paresthesias (VAS)
Time Frame: baseline vs. one day after the last treatment session
Visual analog scale, 0-10, higher score = worse
Secondary Outcomes
- Further neuropathic symptoms (via EORCT CIPN20 questionnaire)(baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session)
- Further neuropathic symptoms (via VAS questionnaire)(baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session)
- Quality of life (via EORCT C30 questionnaire)(baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
High Tone Therapy for Chemotherapy Induced NeuropathyElectrical StimulationChemotherapy-induced Peripheral NeuropathyNCT06048471Vienna Hospital Association14
Not yet recruiting
Not Applicable
CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and TaxanesChemotherapy-induced Peripheral NeuropathyNCT05829967Assiut University60
Not yet recruiting
Phase 2
ANTERN - LAser Nerve ThERapy for chemotherapy NeurotoxicityCancer - Any cancerchemotherapy-induced peripheral neuropathyneurotoxicityNeurological - Other neurological disorderscancerACTRN12619001672145Concord Cancer Centre45
Completed
Phase 2
MC-5A for Chemotherapy Induced Peripheral NeuropathyNeuropathy, ParaneoplasticNCT01261780University of Wisconsin, Madison14
Unknown
Not Applicable
Whole-body Vibration Training to Reduce the Symptoms of Chemotherapy-induced Peripheral NeuropathyChemotherapy-induced Peripheral NeuropathyNCT03032718University of Basel44